99mTc-MIP-1404: Phase II started

Molecular Insight began an open-label, international Phase II trial to evaluate a single IV dose of 99mTc-MIP-1404 followed by SPECT/CT scans 3-6 hours after injection in up to 120 high-risk prostate ...